[Federal Register Volume 80, Number 186 (Friday, September 25, 2015)]
[Notices]
[Pages 57832-57833]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-24331]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Prospective Grant of Start-Up Exclusive Evaluation Option License 
Agreement: Development of Diagnostic Tests and Kits for Detection of 
Pathological Angiogenesis in Cancer

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: This is notice, in accordance with 35 U.S.C. 209 and 37 CFR 
part 404, that the National Institutes of Health, Department of Health 
and Human Services, is contemplating the grant of a Start-Up Exclusive 
Evaluation Option License Agreement to Angio360 Diagnostics, LLC, a 
company having a place of business in Wauwatosa, Wisconsin, to practice 
the inventions embodied in U.S. Provisional Patent Application No. 60/
858,068, entitled ``Differential Gene Expression in Physiological and 
Pathological Angiogenesis,'' filed November 9, 2006 (HHS Ref. No.: E-
285-2006/0-US-01); US Provisional Patent Application No. 60/879,457, 
entitled ``Organ And Tumor Associated Endothelial Markers,'' filed 
January 8, 2007 (HHS Ref. No. E-285-2006/1-US-01); PCT Application No. 
PCT/US2007/072395, entitled ``Differential Gene Expression in 
Physiological and Pathological Angiogenesis,'' filed June 8, 2007 (HHS 
Ref. No. E-285-2006/2-PCT-01); U.S. Patent Application No. 12/514,297, 
entitled ``Differential Gene Expression in Physiological and 
Pathological Angiogenesis,'' filed May 8, 2009 (HHS Ref No. E-285-2006/
2-US-02); Australian Patent No. 2007-317753, entitled ``Differential 
Gene Expression in Physiological and Pathological Angiogenesis,'' filed 
June 28, 2007 (HHS Ref No. E-285-2006/2-AU-03); Canadian Patent 
Application No. 2,669,260, entitled ``Differential Gene Expression in 
Physiological and Pathological Angiogenesis,'' filed June 28, 2007 (HHS 
Ref. No. E-285-2006/2-CA-04); U.S. Patent No.: 8,440,411, entitled 
``Differential Gene Expression in Physiological and Pathological 
Angiogenesis,'' filed March 21, 2011 (HHS Ref. No. E-285-2006/2-US-05); 
U.S. Patent Application No. 13/052,878, entitled ``Differential Gene 
Expression in Physiological and Pathological Angiogenesis,'' filed 
April 16, 2013 (HHS Ref. No.: E-285-2006/2-US-06); and Australian 
Application Patent No.: 2014-200453, entitled ``Differential Gene 
Expression in Physiological and Pathological Angiogenesis,'' filed 
January 28, 2014 (HHS Ref No. E-285-2006/2-AU-07). The patent rights in 
these inventions have been assigned to the Government of the United 
States of America. The territory of the prospective Start-Up Exclusive 
Evaluation Option License Agreement may be worldwide, and the field of 
use may be limited to ``Development of diagnostic tests and kits to 
determine or monitor pathological angiogenesis related to cancer in 
animals or humans.''

[[Page 57833]]

    Upon the expiration or termination of the Start-up Exclusive 
Evaluation Option License Agreement, Angio360 Diagnostics, LLC will 
have the exclusive right to execute a Start-Up Exclusive Patent License 
Agreement which will supersede and replace the Start-up Exclusive 
Evaluation Option License Agreement, with no greater field of use and 
territory than granted in the Start-up Exclusive Evaluation Option 
License Agreement.

DATES: Only written comments and/or applications for a license which 
are received by the NIH Office of Technology Transfer on or before 
October 13, 2015 will be considered.

ADDRESSES: Requests for copies of the patent application(s), inquiries, 
comments, and other materials relating to the contemplated Start-Up 
Exclusive Evaluation Option License Agreement should be directed to: 
Rose M. Freel, Licensing and Patenting Manager, Office of Technology 
Transfer, National Institutes of Health, 6011 Executive Boulevard, 
Suite 325, Rockville, MD 20852-3804; Telephone: (301) 402-9521; 
Facsimile: (301) 402-0220; Email: [email protected]. A signed 
confidentiality nondisclosure agreement will be required to receive 
copies of any patent applications that have not been published or 
issued by the United States Patent and Trademark Office or the World 
Intellectual Property Organization.

SUPPLEMENTARY INFORMATION: This technology describes a method of 
detecting pathological angiogenesis (formation of new blood vessels) 
using the expression levels of certain proteins for the diagnosis of 
cancer or monitoring response to cancer treatment.
    The prospective Start-Up Exclusive Evaluation Option License 
Agreement is being considered under the small business initiative 
launched on October 1, 2011 and will comply with the terms and 
conditions of 35 U.S.C. 209 and 37 CFR part 404. The prospective Start-
Up Exclusive Evaluation Option License Agreement and a subsequent 
Start-Up Exclusive Patent License Agreement may be granted unless the 
NIH receives written evidence and argument, within fifteen (15) days 
from the date of this published notice, that establishes that the grant 
of the contemplated Start-Up Exclusive Evaluation Option License 
Agreement would not be consistent with the requirements of 35 U.S.C. 
209 and 37 CFR part 404.
    Complete applications for a license in the prospective field of use 
that are filed in response to this notice will be treated as objections 
to the grant of the contemplated Start-Up Exclusive Evaluation Option 
License Agreement. Comments and objections submitted to this notice 
will not be made available for public inspection and, to the extent 
permitted by law, will not be released under the Freedom of Information 
Act, 5 U.S.C. 552.

     Dated: September 21, 2015.
Richard U. Rodriguez,
Acting Director, Office of Technology Transfer, National Institutes of 
Health.
[FR Doc. 2015-24331 Filed 9-24-15; 8:45 am]
 BILLING CODE 4140-01-P